

# Daniel A Goldstein

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6263528/publications.pdf>

Version: 2024-02-01

91  
papers

2,252  
citations

218662

26  
h-index

243610

44  
g-index

91  
all docs

91  
docs citations

91  
times ranked

3570  
citing authors

#	ARTICLE	IF	CITATIONS
1	First- and Second-Line Bevacizumab in Addition to Chemotherapy for Metastatic Colorectal Cancer: A United Statesâ€‘Based Cost-Effectiveness Analysis. <i>Journal of Clinical Oncology</i> , 2015, 33, 1112-1118.	1.6	144
2	Mesenchymal Precursor Cells as Adjunctive Therapy in Recipients of Contemporary Left Ventricular Assist Devices. <i>Circulation</i> , 2014, 129, 2287-2296.	1.6	139
3	Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases. <i>Lung Cancer</i> , 2016, 98, 114-117.	2.0	127
4	A global comparison of the cost of patented cancer drugs in relation to global differences in wealth. <i>Oncotarget</i> , 2017, 8, 71548-71555.	1.8	90
5	Cost-Effectiveness of Immune Checkpoint Inhibition in <i>BRAF</i> Wild-Type Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 1194-1202.	1.6	89
6	Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data. <i>Lung Cancer</i> , 2018, 126, 217-223.	2.0	89
7	Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 3727-3732.	1.6	86
8	Trajectories of Injectable Cancer Drug Costs After Launch in the United States. <i>Journal of Clinical Oncology</i> , 2018, 36, 319-325.	1.6	80
9	A Pharmacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Nonâ€‘Small Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	76
10	Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies. <i>Clinical Colorectal Cancer</i> , 2016, 15, 1-6.	2.3	72
11	Increased Levels of Urinary PGE-M, a Biomarker of Inflammation, Occur in Association with Obesity, Aging, and Lung Metastases in Patients with Breast Cancer. <i>Cancer Prevention Research</i> , 2013, 6, 428-436.	1.5	65
12	Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma. <i>European Urology</i> , 2018, 73, 628-634.	1.9	57
13	Estimating (qualityâ€‘adjusted) lifeâ€‘year losses associated with deaths: With application to COVIDâ€‘19. <i>Health Economics (United Kingdom)</i> , 2021, 30, 699-707.	1.7	57
14	Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer. <i>European Urology</i> , 2018, 74, 57-62.	1.9	56
15	Necitumumab in Metastatic Squamous Cell Lung Cancer. <i>JAMA Oncology</i> , 2015, 1, 1293.	7.1	43
16	Association of Immunotherapy With Durable Survival as Defined by Value Frameworks for Cancer Care. <i>JAMA Oncology</i> , 2018, 4, 326.	7.1	43
17	Interventional Pharmacoeconomicsâ€‘A New Discipline for a Cost-Constrained Environment. <i>JAMA Oncology</i> , 2019, 5, 1097.	7.1	43
18	Time Is Money: Optimizing the Scheduling of Nivolumab. <i>Journal of Clinical Oncology</i> , 2018, 36, 3074-3076.	1.6	42

#	ARTICLE	IF	CITATIONS
19	Cost effectiveness and affordability of trastuzumab in sub-Saharan Africa for early stage HER2-positive breast cancer. <i>Cost Effectiveness and Resource Allocation</i> , 2019, 17, 5.	1.5	40
20	Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenibâ€”A cost-effectiveness analysis. <i>PLoS ONE</i> , 2018, 13, e0207132.	2.5	38
21	Cost Effectiveness Analysis of Pharmacokinetically-Guided 5-Fluorouracil in FOLFOX Chemotherapy for Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2014, 13, 219-225.	2.3	35
22	Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 487-493.	4.7	33
23	Financial Toxicity Among Patients with Prostate, Bladder, and Kidney Cancer: A Systematic Review and Call to Action. <i>European Urology Oncology</i> , 2021, 4, 396-404.	5.4	30
24	Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19. <i>JAMA Oncology</i> , 2020, 6, 1694.	7.1	29
25	Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 1700-1709.	1.3	28
26	Association Between Reimbursement Incentives and Physician Practice in Oncology. <i>JAMA Oncology</i> , 2019, 5, 893.	7.1	28
27	Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments. <i>Journal of Clinical Oncology</i> , 2021, 39, 950-955.	1.6	28
28	Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis. <i>Oncologist</i> , 2017, 22, 694-699.	3.7	27
29	Considering Efficacy and Cost, Where Does Ramucirumab Fit in the Management of Metastatic Colorectal Cancer?. <i>Oncologist</i> , 2015, 20, 981-982.	3.7	26
30	A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate-to Poor-Risk Advanced Renal Cell Carcinoma. <i>Oncologist</i> , 2019, 24, 366-371.	3.7	26
31	Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?. <i>Oncologist</i> , 2019, 24, 1469-1478.	3.7	25
32	Opportunities for using in silicoâ€”based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1769-1777.	2.4	25
33	Financial toxicity in cancer careâ€”Edging toward solutions. <i>Cancer</i> , 2017, 123, 1301-1302.	4.1	23
34	Kaposi Sarcoma Inflammatory Cytokine Syndrome (KICS): A Rare but Potentially Treatable Condition. <i>Oncologist</i> , 2017, 22, 623-625.	3.7	23
35	The Financial Impact of Hypofractionated Radiation for Localized Prostate Cancer in the United States. <i>Journal of Oncology</i> , 2019, 2019, 1-8.	1.3	22
36	Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer. <i>Medical Oncology</i> , 2016, 33, 48.	2.5	20

#	ARTICLE	IF	CITATIONS
37	Alternative dosing regimens for atezolizumab: right dose, wrong frequency. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 1153-1155.	2.3	20
38	The cost and value of cancer drugs “ are new innovations outpacing our ability to pay?. <i>Israel Journal of Health Policy Research</i> , 2016, 5, 40.	2.6	18
39	The US Food and Drug Administration’s Approval of Adjuvant Sunitinib for Renal Cell Cancer. <i>JAMA Oncology</i> , 2018, 4, 623.	7.1	17
40	Treatment beyond progression with immune checkpoint inhibitors in non-small-cell lung cancer. <i>Immunotherapy</i> , 2020, 12, 235-243.	2.0	17
41	Adjuvant therapy for pancreas cancer in an era of value based cancer care. <i>Cancer Treatment Reviews</i> , 2016, 42, 10-17.	7.7	16
42	Cabozantinib for patients with advanced hepatocellular carcinoma: a cost-effectiveness analysis. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481987830.	3.2	16
43	Costs and effectiveness of genomic testing in the management of colorectal cancer. <i>Oncology</i> , 2015, 29, 175-83.	0.5	16
44	Clinical Utility of Routine Cardiac Monitoring in Breast Cancer Patients Receiving Trastuzumab. <i>Annals of Pharmacotherapy</i> , 2016, 50, 712-717.	1.9	15
45	Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 532-540.	2.0	14
46	Cancer Drug Pricing and Reimbursement: Lessons for the United States From Around the World. <i>Oncologist</i> , 2016, 21, 907-909.	3.7	13
47	Adjuvant Ipilimumab for Melanoma “The \$1.8 Million per Patient Regimen. <i>JAMA Oncology</i> , 2017, 3, 1628.	7.1	13
48	Denosumab for bone lesions in multiple myeloma “ what is its value?. <i>Haematologica</i> , 2018, 103, 753-754.	3.5	13
49	The Relationship of Diabetes Mellitus to Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer. <i>Oncology</i> , 2021, 99, 555-561.	1.9	13
50	Cost-effectiveness of precision medicine in gastrointestinal stromal tumor and gastric adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 513-523.	1.4	12
51	Dermato-Neuro Syndrome in a Patient Treated With Autologous Stem Cell Transplant for Scleromyxedema. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e213-e215.	0.4	11
52	A real-world analysis of cancer drug wastage due to oversized vials. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2018, 58, 643-646.	1.5	10
53	International health in medical education: students’ experiences and views. <i>Journal of Health Organization and Management</i> , 2007, 21, 575-579.	1.3	9
54	Duration of adjuvant immunotherapy “biologic, clinical and economic considerations. <i>Medical Oncology</i> , 2018, 35, 160.	2.5	9

#	ARTICLE	IF	CITATIONS
55	Interventional Pharmacoeconomics. Cancer Journal (Sudbury, Mass ), 2020, 26, 330-334.	2.0	8
56	Combination therapy patents: a new front in evergreening. Nature Biotechnology, 2021, 39, 1504-1510.	17.5	8
57	Global differences in cancer drug prices: A comparative analysis.. Journal of Clinical Oncology, 2016, 34, LBA6500-LBA6500.	1.6	7
58	The Financial Impact of Fractionation Scheme and Treatment Planning Method for Rectal Cancer in the United States. Clinical Colorectal Cancer, 2019, 18, 209-217.	2.3	6
59	Global differences in cancer drug prices: A comparative analysis.. Journal of Clinical Oncology, 2016, 34, LBA6500-LBA6500.	1.6	6
60	Using Quality-Adjusted Life-Years in Cost-Effectiveness Analyses: Do Not Throw Out the Baby or the Bathwater. Journal of Oncology Practice, 2016, 12, 500-502.	2.5	5
61	A Policy That Encourages Wastage of Expensive Medicationsâ€”The JW Modifier. JAMA Oncology, 2018, 4, 155.	7.1	5
62	Should every candidate for cataract extraction be scheduled to the preoperative clinic? The Rabin Medical Center experience. European Journal of Ophthalmology, 2020, 30, 1268-1271.	1.3	5
63	The Ethical and Practical Challenges of Value-Based Cancer Care at the Patientâ€™s Bedside. JAMA Oncology, 2016, 2, 860.	7.1	4
64	Successful Robotic Excision and Early Chemotherapy for Primary Cardiac Lymphoma. Annals of Thoracic Surgery, 2016, 102, 304-305.	1.3	4
65	Understanding the value of cancer drugsâ€”the devil is in the detail. Cancer, 2016, 122, 2292-2295.	4.1	4
66	Pembrolizumab as firstâ€”line therapy in programmed death ligand 1â€”positive advanced lung cancer: Is it as effective as we think it is?. Cancer, 2017, 123, 3872-3874.	4.1	4
67	Economics of ramucirumab for metastatic colorectal cancer. Expert Review of Pharmacoeconomics and Outcomes Research, 2016, 16, 733-745.	1.4	3
68	The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in realâ€”world earlyâ€”stage breast cancer. Cancer Medicine, 2020, 9, 4603-4612.	2.8	3
69	Mature Versus Registration Studies of Immunoâ€”Oncology Agents: Does Value Improve With Time?. JCO Oncology Practice, 2020, 16, e779-e790.	2.9	3
70	Fractionation scheme and treatment planning method for early glottic cancer in the United States: Economic impact of different medical decisions. Head and Neck, 2020, 42, 1713-1720.	2.0	3
71	Factors Associated With Off-Label Oncology Prescriptions: The Role of Cost and Financing in a Universal Healthcare System. Frontiers in Pharmacology, 2021, 12, 754390.	3.5	3
72	Enabling the Sharing of Single-Dose Vials Through Risk Mitigation to Decrease Financial Toxicity. JAMA Oncology, 2022, 8, 821.	7.1	3

#	ARTICLE	IF	CITATIONS
73	Health Disparities in Prostate Cancer and Approaches to Advance Equitable Care. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, , 360-365.	3.8	3
74	Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab Letter. Clinical Cancer Research, 2020, 26, 2435-2435.	7.0	2
75	Reply to A. Benedict et al. Journal of Clinical Oncology, 2017, 35, 3086-3087.	1.6	1
76	Early Steps in the Value of Cancer Care Many Paths Remain Unexplored. Oncologist, 2018, 23, 391-392.	3.7	1
77	Improving on Tail-of-the-Curve Evaluation With the American Society of Clinical Oncology Value Framework Reply. JAMA Oncology, 2018, 4, 1438.	7.1	1
78	Registration trials in countries without access to US standards of care pitfalls of interpretation. Nature Reviews Clinical Oncology, 2021, 18, 395-396.	27.6	1
79	Metastatic colorectal cancer in a cirrhotic liver with synchronous hepatocellular carcinoma. Annals of Translational Medicine, 2015, 3, 321.	1.7	1
80	Weight-based dosing vs fixed dosing of pembrolizumab: an economic analysis. Clinical Advances in Hematology and Oncology, 2018, 16, 549-551.	0.3	1
81	Subcutaneous Atezolizumab: A Jab Without a Benefit. Clinical Pharmacology in Drug Development, 2022, 11, 134-135.	1.6	1
82	Peptide Vaccines for Treatment of Colon Cancer: Have We Made Progress?. Current Colorectal Cancer Reports, 2014, 10, 477-486.	0.5	0
83	Reply to A. Messori et al, R. Bordonaro et al, and G. Fasola et al. Journal of Clinical Oncology, 2015, 33, 3842-3843.	1.6	0
84	Opposition to Value-Based Cancer Care Interests of Patients or Conflicts of Interest?. Mayo Clinic Proceedings, 2016, 91, 1842-1843.	3.0	0
85	Perspectives in Oncology Drug Pricing Reply. JAMA Oncology, 2016, 2, 402.	7.1	0
86	Information Transparency in the Drug Approval Process Reply. JAMA Oncology, 2018, 4, 1622.	7.1	0
87	Patient-Centered Oncology or Population-Centered Oncology Which Do We Want, and Which Tradeoffs Are We Willing To Accept?. Oncologist, 2019, 24, 288-290.	3.7	0
88	Transitional Cell Carcinoma and Pseudocirrhosis A Case Report and Review of the Literature. Journal of Gastrointestinal and Abdominal Radiology, 2020, 3, S73-S76.	0.3	0
89	Factors associated with off-label (OL) drug use in oncology: The role of cost and financing in a universal healthcare system.. Journal of Clinical Oncology, 2021, 39, e18825-e18825.	1.6	0
90	Prospects of off-label (OL) drug use in oncology: Identifying predicting variables for registration and universal healthcare reimbursement.. Journal of Clinical Oncology, 2021, 39, e18842-e18842.	1.6	0

#	ARTICLE	IF	CITATIONS
91	Strategies for individualizing management of patients with metastatic melanoma: a managed care perspective. American Journal of Managed Care, 2015, 21, S234-41.	1.1	0